Biosimilars are becoming more widely available across Europe, with many payers at each level involve...
Read moreThe aim of this study is to compare the key aspects companies must consider when seeking HTA scienti...
Read moreOrphan drugs have important societal value as they improve patient quality of life and address unmet...
Read moreThis research highlights the variability regarding the scientific advice submission processes and sc...
Read moreUnderstanding payer value and evidence requirements to secure pricing and reimbursement for a novel ...
Read moreThe new NICE oncology appraisal process aims to enable fast-track appraisals, allowing earlier acces...
Read moreHow the pharmaceutical industry is investing in market access training capabilities to address today...
Read moreEarlier this year, the UK government announced support for three new specialist centres capable of c...
Read moreSince 29th July 2016 the NICE appraisal process for oncology indications in England has been modifie...
Read moreWith eight months left before the UK leaves the EU in March 2019, it was hoped that a clear strategy...
Read more